skip to main content


Series A Preferred Stock Financing for Biopharmaceutical Company

Canaan Partners

Represented Canaan Partners in connection with the Series A preferred stock financing of Spyryx Biosciences, Inc., a biopharmaceutical company developing novel inhaled therapeutics for respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disorder (COPD). 

For more information, click here.


Practice Areas

© Shipman & Goodwin LLP 2020. All Rights Reserved.